# Connexin 32 constrains a mesenchymal-like switch in differentiated urothelium and luminal cancers

**Authors:** Jennifer Hinley, Simon C Baker, Andrew S Mason, Grigorios Kyriazis, Omar Masood, Jennifer Southgate

PMC · DOI: 10.26508/lsa.202503427 · Life Science Alliance · 2026-02-17

## TL;DR

This study shows that Connexin 32 helps prevent cancer-like changes in bladder lining cells and could predict more aggressive bladder cancer behavior.

## Contribution

Cx32's role in suppressing migration and proliferation in urothelium and its predictive value in luminal bladder cancer is newly identified.

## Key findings

- Cx32 suppresses TGFβ signaling and mesenchymal-like changes in urothelium.
- Cx32 localization in bladder cancer correlates with more aggressive tumor features.
- Cx32 suppression leads to a wound-healing, migratory urothelial phenotype.

## Abstract

We reveal a coordinating role for Cx32-mediated cell–cell communication in maintaining mitotic-quiescence and limiting migration-associated TGFβ signalling, extracellular matrix remodelling and mesenchymal-like changes in human urothelium. These features establish a dichotomy in the biology of luminal muscle invasive bladder cancers.

The molecular programming of epithelial wound repair provides the origin for the signalling pathways that drive the growth and spread of carcinoma cells. Urothelium is the mitotically quiescent, barrier-forming transitional epithelium of the urinary tract, characterised by uniquely specialised superficial cells and a remarkable regenerative capacity in response to damage. Connexin 32 (Cx32) was expressed by differentiated human urothelium where it predominantly localised to the basolateral borders of superficial urothelial cells. Suppression of Cx32 gap junction intercellular communication did not affect differentiation but instigated the switch to a highly migratory, wound healing phenotype marked by TGFβ-SMAD signalling, ECM-remodelling, and induction of mesenchymal and cell-cycle markers. Immunohistological classification of muscle-invasive bladder cancers revealed Cx32 expression to be informative in luminal tumour biology, with non-membrane localised Cx32 defining a Ki67-high, vimentin-expressing, and TGFβ-activated subset of luminal tumours. Our findings identify Cx32 cell–cell communication as suppressing migratory and proliferative behaviours in normal urothelial differentiation and suggest that Cx32 assessment, within the context of luminal muscle-invasive bladder cancer, can predict more invasive biology. This reveals the potential for differentiated cancers to exhibit EMT.

## Linked entities

- **Genes:** GJB1 (gap junction protein beta 1) [NCBI Gene 2705], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], Smox (Smad on X) [NCBI Gene 31738], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345], PRELID1 (PRELI domain containing 1) [NCBI Gene 737446]
- **Proteins:** Gjb1 (gap junction protein, beta 1), TGFB1 (transforming growth factor beta 1), Smox (Smad on X)
- **Diseases:** bladder cancer (MONDO:0004986)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, ELF3 (E74 like ETS transcription factor 3) [NCBI Gene 1999] {aka EPR-1, ERT, ESE-1, ESX}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], ID3 (inhibitor of DNA binding 3) [NCBI Gene 3399] {aka HEIR-1, bHLHb25}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Gjb1 (gap junction protein, beta 1) [NCBI Gene 29584] {aka Cx32, Cxng}, ATOH8 (atonal bHLH transcription factor 8) [NCBI Gene 84913] {aka HATH6, bHLHa21}, LGALS1 (galectin 1) [NCBI Gene 3956] {aka GAL1, GBP}, GJD3 (gap junction protein delta 3) [NCBI Gene 125111] {aka CX31.9, Cx30.2, GJA11, GJC1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CDH10 (cadherin 10) [NCBI Gene 1008], FOXA1 (forkhead box A1) [NCBI Gene 3169] {aka HNF3A, TCF3A}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, KRT6A (keratin 6A) [NCBI Gene 3853] {aka CK-6C, CK-6E, CK6A, CK6C, CK6D, K6A}, KRT6B (keratin 6B) [NCBI Gene 3854] {aka CK-6B, CK6B, K6B, KRTL1, PC2, PC4}, UPK1A (uroplakin 1A) [NCBI Gene 11045] {aka TSPAN21, UP1A, UPIA, UPKA}, ID1 (inhibitor of DNA binding 1) [NCBI Gene 3397] {aka ID, bHLHb24}, CDH3 (cadherin 3) [NCBI Gene 1001] {aka CDHP, HJMD, PCAD}, ACKR3 (atypical chemokine receptor 3) [NCBI Gene 57007] {aka CMKOR1, CXC-R7, CXCR-7, CXCR7, GPR159, RDC-1}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, CLDN4 (claudin 4) [NCBI Gene 1364] {aka CPE-R, CPER, CPETR, CPETR1, WBSCR8, hCPE-R}, Gjd2 (gap junction protein, delta 2) [NCBI Gene 50564] {aka Cx36, Cxns, Gja9}, UPK3A (uroplakin 3A) [NCBI Gene 7380] {aka UP3A, UPIII, UPIIIA, UPK3}, CDCA2 (cell division cycle associated 2) [NCBI Gene 157313] {aka PPP1R81, Repo-Man}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, GJB7 (gap junction protein beta 7) [NCBI Gene 375519] {aka CX25, bA136M9.1, connexin25}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, KRT5 (keratin 5) [NCBI Gene 3852] {aka CK5, DDD, DDD1, EBS1, EBS2, EBS2A}, GJA9 (gap junction protein alpha 9) [NCBI Gene 81025] {aka CX58, CX59, GJA10}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, GJB1 (gap junction protein beta 1) [NCBI Gene 2705] {aka CMTX, CMTX1, CX32}, CLDN3 (claudin 3) [NCBI Gene 1365] {aka C7orf1, CPE-R2, CPETR2, HRVP1, RVP1}, Cdh1 (cadherin 1) [NCBI Gene 12550] {aka ARC-1, E-cad, Ecad, L-CAM, UVO, Um}, VIM (vimentin) [NCBI Gene 7431], UPK3B [NCBI Gene 80761], GJA4 (gap junction protein alpha 4) [NCBI Gene 2701] {aka CX37}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, CAV1 (caveolin 1) [NCBI Gene 857] {aka BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21}, KRT13 (keratin 13) [NCBI Gene 3860] {aka CK13, K13, WSN2}, Smad3 (SMAD family member 3) [NCBI Gene 17127] {aka Madh3}, KRT14 (keratin 14) [NCBI Gene 3861] {aka CK14, EBS1, EBS1A, EBS1B, EBS1C, EBS1D}, ID2 (inhibitor of DNA binding 2) [NCBI Gene 3398] {aka GIG8, ID2A, ID2H, bHLHb26}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, Gjb1 (gap junction protein, beta 1) [NCBI Gene 14618] {aka Cnx32, Cx32, Cxng, connexin-32}, CLDN7 (claudin 7) [NCBI Gene 1366] {aka CEPTRL2, CLDN-7, CPETRL2, Hs.84359, claudin-1}, Vim (vimentin) [NCBI Gene 22352], RGCC (regulator of cell cycle) [NCBI Gene 28984] {aka C13orf15, RGC-32, RGC32, bA157L14.2}, UPK1B (uroplakin 1B) [NCBI Gene 7348] {aka TSPAN20, UPIB, UPK1}, CCDC80 (coiled-coil domain containing 80) [NCBI Gene 151887] {aka CL2, DRO1, LINC01279, SSG1, URB, okuribin}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, UPK2 (uroplakin 2) [NCBI Gene 7379] {aka UP2, UPII}, GJD2 (gap junction protein delta 2) [NCBI Gene 57369] {aka CX36, GJA9}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, Snai2 (snail family zinc finger 2) [NCBI Gene 20583] {aka Slug, Slugh, Snail2}, TJP2 (tight junction protein 2) [NCBI Gene 9414] {aka C9DUPq21.11, DFNA51, DUP9q21.11, FHCA1, PFIC4, X104}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}
- **Diseases:** basal/squamous (MESH:D002294), Neuroendocrine-like (MESH:D018358), basal tumours (MESH:D009369), NHU (MESH:D014526), bladder cancer (MESH:D001749), hepatocellular carcinoma (MESH:D006528), metastasis (MESH:D009362), MIBCs (MESH:D000093284)
- **Chemicals:** prostaglandin E2 (MESH:D015232), TRIzol (MESH:C411644), 18alpha-GA (MESH:C119129), MG132 (MESH:C072553), luminal (MESH:D010634), Hoechst 33258 (MESH:D006690), water (MESH:D014867), PD (MESH:D010165), IP3 (MESH:D015544), ethanol (MESH:D000431), hydrochloric acid (MESH:D006851), SDS (MESH:D012967), MES (MESH:C004550), CaCl2 (MESH:D002122), biotin (MESH:D001710), TZ (MESH:D000077288), PI (MESH:D010716), IRDye800 (MESH:C427728), methanol (MESH:D000432), adenosine (MESH:D000241), paraffin (MESH:D010232), polymer (MESH:D011108), Bis-Tris (MESH:C026272), Triton X-100 (MESH:D017830), wax (MESH:D014885), EDTA (MESH:D004492), 5-Bromo-2'-deoxyuridine (MESH:D001973), xylene (MESH:D014992), PD153035 (MESH:C088860), citric acid (MESH:D019343), calcium (MESH:D002118), polyA (MESH:D011061), DMSO (MESH:D004121), T007 (MESH:C458508), formalin (MESH:D005557), PVDF (MESH:C024865), PBS (MESH:D007854), 3'3-diaminobenzidine (MESH:D015100), haematoxylin (MESH:D006416), Alexa 594 (MESH:C417664), RhoD (MESH:C051311), puromycin (MESH:D011691), LY (MESH:C017475), G418 (MESH:C010680), propidium iodide (MESH:D011419), Ca2+ (-), acetone (MESH:D000096), peroxide (MESH:D010545), MOPS (MESH:C008550)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** C in 0, C in 10, T134A
- **Cell lines:** HT1376 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_1292), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), NHU — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_JX41), PT67 — Mus musculus (Mouse), Transformed cell line (CVCL_9093)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12912911/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12912911/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC12912911/full.md

---
Source: https://tomesphere.com/paper/PMC12912911